Literature DB >> 7122111

Clinical pharmacokinetics applied to patients with intractable pain: studies with pethidine.

Christopher J Glynn1, Laurence E Mather.   

Abstract

The minimum effective analgetic blood concentration (MEAC) of pethidine following intravenous administration was identified in 3 patients with intractable pain. In two patients this value remained the same whether the pethidine was given intravenously, orally or rectally. In the third patient, whose eneral bioavailability was only 20%, the MEAC was not obtained. However, intramuscular administration reliably achieved the MEAC and was useful clinically. During the study period of 3-12 months, the individual patient's MEAC remained similar. Two patients developed dependence on, and tolerance to, pethidine but neither the dependence nor the tolerance appeared to be related to the MEAC. These studies confirm the importance of clinical pharmacokinetic measurements in the investigation and treatment of patients with intractable pain.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7122111     DOI: 10.1016/0304-3959(82)90013-6

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  4 in total

Review 1.  Adverse effects of systemic opioid analgesics.

Authors:  S A Schug; D Zech; S Grond
Journal:  Drug Saf       Date:  1992 May-Jun       Impact factor: 5.606

Review 2.  Intravenous anaesthetic agents. Pharmacokinetic-pharmacodynamic relationships.

Authors:  B N Swerdlow; F O Holley
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

Review 3.  Treatment principles for the use of opioids in pain of nonmalignant origin.

Authors:  S A Schug; A F Merry; R H Acland
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

Review 4.  Clinical features and management of intoxication due to hallucinogenic drugs.

Authors:  J B Leikin; A J Krantz; M Zell-Kanter; R L Barkin; D O Hryhorczuk
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Sep-Oct
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.